ArticleProtoplasma2026
The 26S proteasome engages in priming explants with auxin plus cytokinin for somatic embryogenesis of Coffea canephora.
Article in Protoplasma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracellular reorganization and the induction of somatic embryogenesis (SE) are essential for generating viable plantlets. To better understand how protein degradation via the 26S proteasome impacts the state of explants used for SE in C. canephora, we inhibited proteasome function with MG132. We then analyzed the SE progression from early developmental stages to plantlet photomorphogenesis using histological and histochemical techniques. Treatment with MG132 successfully inactivated the 26S proteasome in the explants. Following inactivation, morphological features and histochemical signals for reserve materials and protein bodies decreased during the first 21 days of culture. Interestingly, the subsequent development of globular and cotyledonary stages from MG132-exposed explants occurred at a faster rate than in the control group. These embryos exhibited intense PAS and XP staining, well-bifurcated cotyledons, and enhanced root development. While the overall population of the globular and cotyledonary somatic embryo population was reduced by approximately 19% in MG132-treated explants, this decrease was reversible in recovery cultures, proving that the observed effects were likely due to 26S function rather than permanent cellular damage. Furthermore, the expression of genes related to SE (CcWOX, CcBBM1, CcAGL15), PGR biosynthesis (CcYUC1, CcIPT1) and PGR signaling (CcARF5, CcAHK1) were markedly shifted during the embryo stages in treated explants. Collectively, our results suggest that the proteasome 26S is involved in establishing suitable explant conditions for SE and likely facilitates the downstream morphological transitions required for robust embryo development.
Indexed as
Identifiers
41951958What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.